Schizophrenia is Increasing Especially in Low and Middle-Income Countries

According to Schizophrenia Statistics, the prevalence of schizophrenia varies by region and is estimated to be around 1% of the global population.

Prevalence and Burden of Schizophrenia Statistics

Schizophrenia is a common disease but it can be a serious and chronic one.

The term schizophrenia is used to indicate how many people are currently living with a specific condition at or during a particular condition of time.

• About 1% of the global population is diagnosed with schizophrenia.
• Approximately 1.2% of Americans (3.2 million) have the disorder.
• About 1.5 million people will be diagnosed with schizophrenia this year around the world.
• Most of the people with schizophrenia disorder are between the age of 16 to 25 years.
• Schizophrenia is one of the top 15 leading causes of disability worldwide.
• The average potential of life lost for individuals with schizophrenia in the United States is 28.5 years.
• About 4.9% of people with the disorder die by suicide, the rate of that is greater than the general population, with higher risks in the early stages of illness.

How Common is Schizophrenia?

• About 20 million people worldwide have this mental disorder.
• The annual number of new cases of schizophrenia is 1.5% per 10,000 people.
• About 20% of people with schizophrenia attempt suicide at least once.
• Schizophrenia affects approximately 24 million people or 1 in 300 about 0.32% worldwide.
• The rate of occurrence among adults is 1 in 222 (0.45%).
• People with schizophrenia are 2 to 3 times more likely to die early than the general population.
• Approximately 50% of people in mental hospitals have schizophrenia diagnoses.
• Only 31.3% of people with psychosis receive treatment.
• Schizophrenia is diagnosed 1.4 times more frequently in males than females.
• The mean age of the first hospital. admission for treatment of schizophrenia is between 25 to 35 years.

Prevalence of Mental Illness Statistics

Mental illness is the most common problem among people worldwide. Some age groups experience more mental illness than others. It is estimated that the number of women suffering from mental illness is more than men. In the United States, the prevalence of mental illness in the past year is more common among females than males.

• 44.7 million Americans struggled with mental illness in the year 2022.
• In 2021, 1.2% of US men received mental health treatment or counseling.
• Of the majority of US adults not receiving mental health services, a total of 43% could not afford the cost of treatment.
• In 2020, there were 12,275 registered mental health treatment facilities in the US, within those, 9,634 were less than 24-hour outpatient facilities while 1,806 facilities were 24-hour inpatient facilities.
• Around 27% of females reported some type of mental illness in the year 2022 as compared to 18% of males.
• Around 8.1% of female respondents and 7.2% of male respondents in the United States reported having suffered from co-occurring mental illness and substance disorder in the past year 2022.

Top 5 Companies that Provide Schizophrenia Drugs

Schizophrenia Drugs manufactured by top Companies implementing various growth strategies such as new product launches.

Danish Pharmaceutical Company Lundbeck

• Among the products of Danish pharmaceutical company Lundbeck, the largest revenue in 2022 was made from Brintellix/Trintellix.
• The revenues from Brintellix/Trintellix reached roughly 4.3 billion Danish kroner that year.
• It was followed by Rexulti/Rxulti, with a revenue of roughly 3.9 billion Danish kroner.
• H. Lundbeck A/S is a Danish pharmaceutical company founded in 1915 with its headquarters in Copenhagen. The key products produced by the company are pharmaceuticals for the nervous system.

Revenue of Lundbeck’s top products in 2021 and 2022 (in million DKK)

Janssen Pharmaceuticals

• This company provides Invega Sustenna, which is an injectable medication for the treatment of schizophrenia.
• In 2022, Johnson & Johnson generated approximately 95 billion U.S. dollars in sales.
• As of 2022, it was ranked as the leading pharmaceutical company worldwide in terms of total revenue generated.
• As of 2022, Johnson and Johnson was not among the big pharmaceutical companies with the highest R&D intensity.
• Janssen Pharmaceuticals is a part of Johnson & Johnson, the USA-based Healthcare Corporation.
• Around $4.5 billion investments in research & development annually.

Pfizer

• Pfizer provides Geodon, an oral medication for the treatment of schizophrenia.
• In 2022, the company’s total revenue exceeded 100 billion U.S. dollars for the first time, a record among global drug manufacturers.
• Pfizer’s products are available in many countries worldwide and as of 2022, the company had some 170 research and development projects.

Eli Lilly and Company

• Eli Lilly and Company provides Zyprexa, an oral medication for the treatment of schizophrenia.
• In 2022, the company generated 28.5 billion U.S. dollars of revenue.  
• In 2022, the company generated some 1.75 billion U.S. dollars of its revenue in Japan.

AstraZeneca

• AstraZeneca provides Seroquel, an oral medication for the treatment of schizophrenia.
• In 2022, British-Swedish biopharmaceutical company AstraZeneca generated revenues of some 43 billion U.S. dollars, the fifth consecutive year with significant growth.

COVID-19 Impact on Patients Have Schizophrenia

COVID-19 has a significant impact on mental health worldwide. People with schizophrenia are particularly vulnerable to its effects. Propels with schizophrenia experienced increased stress and anxiety due to fear of coronavirus spreading and change in routine. People with schizophrenia are known to suffer from a higher prevalence of respiratory tract infections than the general population.

• The prevalence of schizophrenia in 7341 Korean patients with COVID-19 was 3.6%.
• The prevalence of schizophrenia during the crisis of COVID-19 was higher at 5.4%.
• 50,750 patients admitted to hospital for COVID-19 in France.
• The prevalence of schizophrenia was 1.6% in the West.
• The United States reported a prevalence of 2% of psychotic disorders in 62,354 patients with COVID-19.

Old age and clinical comorbidities raise mortality rates for patients with COVID-19.

• About 70% of all patients with schizophrenia often have 1 or more clinical conditions.
• The smoking rate among patients with schizophrenia increased from 50% to 90% during the pandemic.

How common is depression in the United States?

• Depression is one of the most common disorders in the United States.
• Around 8.3% of US adults reported a major depressive episode in the last year 2022.
• 75% of women aged 18-20 reported major depressive episodes in 2022 compared to 8.6% of women aged 40-44 years.
• Around 32% of those in the US with a major depressive episode in the past year had serious thoughts of suicide compared to just 2% of those who did not have any major depressive episode.

Mental Health Treatment in the United States Statistics

Treatment of mental health issues can come in many different forms and depend on the type of issues and severity of disorders. The common treatment methods include behavioral therapy, psychotherapy, and support groups.

• In 2021, around 50% of respondents in the United States with a major depressive episode reported they received treatment from a general family doctor.
• 43% of adults in the United States reported that they do not receive mental health services.
• 35% of adults said that they did not know where to go for such services.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF